A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Elucidation of the genetic factors underlying chronic liver disease may reveal new therapeutic targets. METHODS: We used exome sequence data and electronic health records from 46,544 participants in the DiscovEHR human genetics study to identify genetic variants associated with serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Variants that were replicated in three additional cohorts (12,527 persons) were evaluated for association with clinical diagnoses of chronic liver disease in DiscovEHR study participants and two independent cohorts (total of 37,173 persons) and with histopathological severity of liver disease in 2391 human liver samples. RESULTS: ). Among DiscovEHR study participants, this variant was associated with a reduced risk of alcoholic liver disease (by 42% [95% confidence interval {CI}, 20 to 58] among heterozygotes and by 53% [95% CI, 3 to 77] among homozygotes), nonalcoholic liver disease (by 17% [95% CI, 8 to 25] among heterozygotes and by 30% [95% CI, 13 to 43] among homozygotes), alcoholic cirrhosis (by 42% [95% CI, 14 to 61] among heterozygotes and by 73% [95% CI, 15 to 91] among homozygotes), and nonalcoholic cirrhosis (by 26% [95% CI, 7 to 40] among heterozygotes and by 49% [95% CI, 15 to 69] among homozygotes). Associations were confirmed in two independent cohorts. The rs72613567:TA variant was associated with a reduced risk of nonalcoholic steatohepatitis, but not steatosis, in human liver samples. The rs72613567:TA variant mitigated liver injury associated with the risk-increasing PNPLA3 p.I148M allele and resulted in an unstable and truncated protein with reduced enzymatic activity. CONCLUSIONS: A loss-of-function variant in HSD17B13 was associated with a reduced risk of chronic liver disease and of progression from steatosis to steatohepatitis. (Funded by Regeneron Pharmaceuticals and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides PNPLA3 p.I148M and TM6SF2 p.E167K, additional variants, including common risk variants in MBOAT7 , GCKR , GPAM , protective variants in HSD17B13 , APOE and MTARC1, and rare variants ( e.g. in APOB , MTTP, CIDEB and ATG7 ), have been robustly associated with the risk of progressive MASLD. 199 -205”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [200]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in the periportal hepatocyte-enriched genes HSD17B13152 and PNPLA3153 are associated with NASH”
From Distinct hepatocyte identities in liver homeostasis and regeneration (2023) · cites this paper as [152]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Some of the most important human metabolic disease genes have been identified using germline genetic methods such as GWAS and whole exome sequencing42-44.”
From Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease (2023) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“To demonstrate this, we examined the trans associations with a splice variant in HSD17B13 (rs72613567), known to protect against chronic liver disease42.”
From Rare variant associations with plasma protein levels in the UK Biobank (2023) · cites this paper as [42]
In the citing paper
“These findings inform the prioritization of therapeutic targets, providing clues to potential on-target side effects and opportunities for drug repurposing87–89.”
From A brief history of human disease genetics (2020) · cites this paper as [88]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Self-citationGenetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Self-citationWilliams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Self-citationKozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234
Self-citationYounossi, Z. M., Stepanova, M., Afendy, M., Fang, Y., Younossi, Y., Mir, H., & Srishord, M. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.03.020 · Cited by 1,073
Lazo, M., Hernaez, R., Eberhardt, M. S., Bonekamp, S., Kamel, I., Guallar, E., Koteish, A., Brancati, F. L., & Clark, J. M. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws448 · Cited by 797
Mancina, R. M., Dongiovanni, P., Petta, S., Pingitore, P., Meroni, M., Rametta, R., Borén, J., Montalcini, T., Pujia, A., Wiklund, O., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.032 · Cited by 676
Self-citationLiu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5309 · Cited by 623
Self-citationBuch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H. D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3417 · Cited by 565
Cited by
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Vogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
“Similar to PNPLA3, a new disease mechanism has been suggested by discovery of a variant of 17-beta hydroxysteroid dehydrogenase 13, encoded by the HSD17B13 gene, a poorly characterized enzyme present in hepatocytes (Abul-Husn et al., 2018).”
BackgroundGinès, P., Krag, A., Abraldes, J. G., Solà, E., Fabrellas, N., & Kamath, P. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01374-x · Cited by 1,663
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
Cotter, T. G., & Rinella, M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.052 · Cited by 1,198
Crabb, D. W., Im, G. Y., Szabo, G., Mellinger, J. L., & Lucey, M. R. (2020) · Hepatology · doi:10.1002/hep.30866 · Cited by 922
“described a polymorphism related to a hepatic lipid droplet protein hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13), the presence of which confers protection against the progression from steatosis to steatohepatitis in alcohol-associated and non-alcohol-associated chronic liver disease.(110) Co-existent heavy alcoh…”
Stefan, N., Häring, H.-U., & Cusi, K. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30154-2 · Cited by 837
Duell, P. B., Welty, F. K., Miller, M., Chait, A., Hammond, G., Ahmad, Z., Cohen, D. E., Horton, J. D., Pressman, G. S., Toth, P. P., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000153 · Cited by 727
A brief history of human disease genetics
Claussnitzer, M., Cho, J. H., Collins, R., Cox, N. J., Dermitzakis, E. T., Hurles, M. E., Kathiresan, S., Kenny, E. E., Lindgren, C. M., MacArthur, D. G., et al. (2020) · Nature · doi:10.1038/s41586-019-1879-7 · Cited by 697
NAFLD and cardiovascular diseases: a clinical review
Kasper, P., Martin, A., Lang, S., Kütting, F., Goeser, T., Demir, M., & Steffen, H.-M. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01709-7 · Cited by 632
“A splice variant in HSD17B13 (encoding the hepatic lipid droplet protein hydroxysteroid 17-beta dehydrogenase 13) was associated with decreased serum aminotransferase levels as well as a reduced risk of NASH or fibrosis and also mitigated the risk of liver injury in persons who were genetically predisposed to fatty li…”
BackgroundLipid droplet biogenesis and functions in health and disease
Zadoorian, A., Du, X., & Yang, H. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00845-0 · Cited by 617
“Two variants of 17β-hydroxysteroid dehydrogenase 13 (17β-HSD13), rs72613567:TA and rs6834314, which have retinol dehydrogenase activity 197 , have been suggested to protect against PNPLA3 I148M-induced hepatic fibrosis 198,199 .”
Advances in molecular classification and precision oncology in hepatocellular carcinoma
Rebouissou, S., & Nault, J.-C. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.017 · Cited by 575
Exome sequencing and characterization of 49,960 individuals in the UK Biobank
Van Hout, C. V., Tachmazidou, I., Backman, J. D., Hoffman, J. D., Liu, D., Pandey, A. K., Gonzaga-Jauregui, C., Khalid, S., Ye, B., Banerjee, N., et al. (2020) · Nature · doi:10.1038/s41586-020-2853-0 · Cited by 561
Self-citationPast, present and future perspectives in nonalcoholic fatty liver disease
Sanyal, A. J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0144-8 · Cited by 522
Alpha 1 -Antitrypsin Deficiency
Strnad, P., McElvaney, N. G., & Lomas, D. A. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1910234 · Cited by 515
Anstee, Q. M., Darlay, R., Cockell, S., Meroni, M., Govaere, O., Tiniakos, D., Burt, A. D., Bedossa, P., Palmer, J., Liu, Y.-L., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.003 · Cited by 499
“11,13 The current study found a protective effect against NAFLD generally, with the strongest effect related to the SNPs rs9992651 and rs13118664.”
BackgroundResultInfluentialSelf-citationEuropean Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 471
Govaere, O., Cockell, S., Tiniakos, D., Queen, R., Younes, R., Vacca, M., Alexander, L., Ravaioli, F., Palmer, J., Petta, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba4448 · Cited by 479
Obesity as a multisystem disease: Trends in obesity rates and obesity‐related complications
Sarma, S., Sockalingam, S., & Dash, S. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14290 · Cited by 435
“For example, a proteintruncating variant in HSD17B13, which encodes a hepatic lipid droplet protein, protects against chronic liver disease in those with hepatic steatosis.(93)”
BackgroundRoden, D. M., McLeod, H. L., Relling, M. V., Williams, M. S., Mensah, G. A., Peterson, J. F., & Van Driest, S. L. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31276-0 · Cited by 427
Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank
Szustakowski, J. D., Balasubramanian, S., Kvikstad, E., Khalid, S., Bronson, P. G., Sasson, A., Wong, E., Liu, D., Wade Davis, J., Haefliger, C., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00885-0 · Cited by 401
Self-citationUpdate on NAFLD genetics: From new variants to the clinic
Trépo, E., & Valenti, L. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.02.020 · Cited by 393
Bianco, C., Jamialahmadi, O., Pelusi, S., Baselli, G., Dongiovanni, P., Zanoni, I., Santoro, L., Maier, S., Liguori, A., Meroni, M., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.024 · Cited by 385
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
“In the DiscovEHR human genetics study, truncated loss-of-function variant in hydroxysteroid 17β-dehydrogenase 13 (HSD17B13 rs72613567: TA), a lipid droplet-associated protein that is enriched in liver and hepatocyte with retinol dehydrogenase activity, was found to associate with decreased levels of ALT and AST and im…”
BackgroundLoomba, R., Lim, J. K., Patton, H., & El-Serag, H. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.053 · Cited by 357
Alcohol-associated liver disease
Mackowiak, B., Fu, Y., Maccioni, L., & Gao, B. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176345 · Cited by 359
Israelsen, M., Francque, S., Tsochatzis, E. A., & Krag, A. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01811-7 · Cited by 348
Personalized Medicine and the Power of Electronic Health Records
Abul-Husn, N. S., & Kenny, E. E. (2019) · Cell · doi:10.1016/j.cell.2019.02.039 · Cited by 355
“We can expect that EHR-linked biobanks will increasingly be used in genomics-driven drug discovery (Abul-Husn et al., 2018; Dewey et al., 2016a; Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators et al., 2016) and drug repurposing.”
BackgroundMethodSelf-citationChallenges and opportunities in NASH drug development
Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N. (2023) · Nature Medicine · doi:10.1038/s41591-023-02242-6 · Cited by 353
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Pafili, K., & Roden, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101122 · Cited by 330
“Furthermore, the splice variant (rs72613567:TA) encoding the hepatic lipid droplet protein hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13), which has enzymatic activity against several bioactive lipid species implicated in lipid-mediated inflammation, reduced the risk of fibrosis [56] and NASH but not steatosis [57…”
BackgroundMa, Y., Belyaeva, O. V., Brown, P. M., Fujita, K., Valles, K., Karki, S., de Boer, Y. S., Koh, C., Chen, Y., Du, X., et al. (2019) · Hepatology · doi:10.1002/hep.30350 · Cited by 312
NAFLD in children: new genes, new diagnostic modalities and new drugs
Nobili, V., Alisi, A., Valenti, L., Miele, L., Feldstein, A. E., & Alkhouri, N. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0169-z · Cited by 309
Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology
Eslam, M., & George, J. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0212-0 · Cited by 308
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
“…study in 2018 determined that a splice variant (rs72613567) in HSD17B13 , with an estimated minor allele frequency of 18%, disrupts mRNA splicing and generates unstable proteins with reduced activity, which confers a protective effect against the development of MASH and advanced fibrosis 122,123 .”
Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors
Juanola, O., Martínez-López, S., Francés, R., & Gómez-Hurtado, I. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18105227 · Cited by 302
“Recently, it has been described that several polymorphisms including rs72613567, rs143404524, and rs62305723 have a protective role in liver injury as they have been associated with reduced serum hepatic ALT and AST levels, diminished risk for liver damage, progression toward HCC and liver-related mortality in alcohol…”
BackgroundHarrison, S. A., Neff, G., Guy, C. D., Bashir, M. R., Paredes, A. H., Frias, J. P., Younes, Z., Trotter, J. F., Gunn, N. T., Moussa, S. E., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.08.004 · Cited by 280
Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity
Akbari, P., Gilani, A., Sosina, O., Kosmicki, J. A., Khrimian, L., Fang, Y.-Y., Persaud, T., Garcia, V., Sun, D., Li, A., et al. (2021) · Science · doi:10.1126/science.abf8683 · Cited by 276
Self-citationHarrison, S. A., Rossi, S. J., Paredes, A. H., Trotter, J. F., Bashir, M. R., Guy, C. D., Banerjee, R., Jaros, M. J., Owers, S., Baxter, B. A., et al. (2020) · Hepatology · doi:10.1002/hep.30590 · Cited by 262
Gellert‐Kristensen, H., Richardson, T. G., Davey Smith, G., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Stender, S. (2020) · Hepatology · doi:10.1002/hep.31238 · Cited by 252
“(11) For each of the three variants, individuals carrying two risk alleles have a 2-fold to 4-fold higher risk of developing fibrosis, cirrhosis, and HCC compared with those carrying zero risk alleles.(11-17) These relatively large effect sizes have spurred an interest in using the variants prognostically in fatty liv…”
BackgroundMethodInfluentialSelf-citationUganda Genome Resource Enables Insights into Population History and Genomic Discovery in Africa
Gurdasani, D., Carstensen, T., Fatumo, S., Chen, G., Franklin, C. S., Prado-Martinez, J., Bouman, H., Abascal, F., Haber, M., Tachmazidou, I., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.004 · Cited by 255
“As with previous studies, we find that in spite of the lower absolute number of missense mutations (149,251 in UG2G and 69,761 in UK10K Avon Longitudinal Study of Children and Parent [ALSPAC]) in Europeans, these form a higher relative proportion of total variation (0.4%and 0.5% in UG2GandUK10K, respectively, p 2310 1…”
BackgroundInfluentialNon-alcoholic fatty liver disease: Definition and subtypes
Han, S. K., Baik, S. K., & Kim, M. Y. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0424 · Cited by 245
“A recent study showed that a loss-of-function variant of HSD17B13 was associated with a reduced risk of chronic liver disease and progression from steatosis to steatohepatitis, highlighting it as a potential therapeutic target.(88) Many other genes involved in carbohydrate and lipid me-”
BackgroundHutchison, A. L., Tavaglione, F., Romeo, S., & Charlton, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.030 · Cited by 250
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Lee, K.-C., Wu, P.-S., & Lin, H.-C. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0237 · Cited by 246
Multiomics study of nonalcoholic fatty liver disease
Sveinbjornsson, G., Ulfarsson, M. O., Thorolfsdottir, R. B., Jonsson, B. A., Einarsson, E., Gunnlaugsson, G., Rognvaldsson, S., Arnar, D. O., Baldvinsson, M., Bjarnason, R. G., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01199-5 · Cited by 236
The cell biology of the hepatocyte: A membrane trafficking machine
Schulze, R. J., Schott, M. B., Casey, C. A., Tuma, P. L., & McNiven, M. A. (2019) · Journal of Cell Biology · doi:10.1083/jcb.201903090 · Cited by 236
Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD
Mashek, D. G. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101115 · Cited by 232
“The rs72613567:TA allele results in a truncated and lower abundant protein associated with a reduction in numerous chronic liver diseases including NAFLD and non-alcoholic cirrhosis [174].”
BackgroundNAFLD‐related hepatocellular carcinoma: The growing challenge
Shah, P. A., Patil, R., & Harrison, S. A. (2023) · Hepatology · doi:10.1002/hep.32542 · Cited by 230
“[100] As noted in previous studies, different genetic polymorphisms had variable effects on HCC risks; HSD17B13, for example, has protective effects, whereas others like PNPLA3 (I148M variant) increase the risk.[101,102] PRS with weighted effect of each genetic variant likely would be more predictive.”
ResultMetabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver
Kaya, E., & Yilmaz, Y. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00178 · Cited by 226
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
Impact of non-invasive biomarkers on hepatology practice: past, present and future
Anstee, Q. M., Castera, L., & Loomba, R. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.026 · Cited by 224
Metabolic drivers of non-alcoholic fatty liver disease
Bence, K. K., & Birnbaum, M. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101143 · Cited by 221
Immunological mechanisms and therapeutic targets of fatty liver diseases
Wang, H., Mehal, W., Nagy, L. E., & Rotman, Y. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00579-3 · Cited by 221
From target discovery to clinical drug development with human genetics
Trajanoska, K., Bhérer, C., Taliun, D., Zhou, S., Richards, J. B., & Mooser, V. (2023) · Nature · doi:10.1038/s41586-023-06388-8 · Cited by 220
“Similarly, genetics coupled with EMR data from 46,544 participants in the DiscovEHR study identified loss-of-function variants in HSD17B13 that were associated with slower progression of liver steatosis to steatohepatitis 115 .”
BackgroundLiver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Parola, M., & Pinzani, M. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101231 · Cited by 218
Chen, Y., Du, X., Kuppa, A., Feitosa, M. F., Bielak, L. F., O’Connell, J. R., Musani, S. K., Guo, X., Kahali, B., Chen, V. L., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01497-6 · Cited by 215
“LYPLAL1 may affect body fat distribution and indirectly affect NAFLD, helping to explain its particularly weak effect 57,58 .”
BackgroundTillman, E. J., & Rolph, T. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601290 · Cited by 213
“Three risk alleles uncovered in genome-wide association studies on NASH patients include polymorphisms in the LDassociated genes HSD17B13 (114), PNPLA3 (115), and TM6SF2 (116).”
BackgroundLindén, D., Ahnmark, A., Pingitore, P., Ciociola, E., Ahlstedt, I., Andréasson, A.-C., Sasidharan, K., Madeyski-Bengtson, K., Zurek, M., Mancina, R. M., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.01.013 · Cited by 211
Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD
Rinella, M. E., Tacke, F., Sanyal, A. J., & Anstee, Q. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.019 · Cited by 209
Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting
Avila, M. A., Dufour, J.-F., Gerbes, A. L., Zoulim, F., Bataller, R., Burra, P., Cortez-Pinto, H., Gao, B., Gilmore, I., Mathurin, P., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319720 · Cited by 206
Vujkovic, M., Ramdas, S., Lorenz, K. M., Guo, X., Darlay, R., Cordell, H. J., He, J., Gindin, Y., Chung, C., Myers, R. P., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01078-z · Cited by 205
Self-citationLeveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease
Romeo, S., Sanyal, A., & Valenti, L. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.12.002 · Cited by 202
Rare variant associations with plasma protein levels in the UK Biobank
Dhindsa, R. S., Burren, O. S., Sun, B. B., Prins, B. P., Matelska, D., Wheeler, E., Mitchell, J., Oerton, E., Hristova, V. A., Smith, K. R., et al. (2023) · Nature · doi:10.1038/s41586-023-06547-x · Cited by 193
“In line 738, the authors indeed repeated the analysis.”
BackgroundNegi, C. K., Babica, P., Bajard, L., Bienertova-Vasku, J., & Tarantino, G. (2022) · Metabolism · doi:10.1016/j.metabol.2021.154925 · Cited by 190
Hepatic lipid droplet homeostasis and fatty liver disease
Seebacher, F., Zeigerer, A., Kory, N., & Krahmer, N. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2020.04.011 · Cited by 190
Staufer, K., Huber-Schönauer, U., Strebinger, G., Pimingstorfer, P., Suesse, S., Scherzer, T.-M., Paulweber, B., Ferenci, P., Stimpfl, T., Yegles, M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.040 · Cited by 190
“domain-containing protein 3 (PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2), Membrane-bound O-acyltransferase domain-containing protein 7 (MBOAT7), or 17bhydroxysteroid dehydrogenase type 13.(14,15) Furthermore, increased endogenous ethanol (EtOH) levels due to alcoholproducing microbiota,(16) or insulin-depen…”
BackgroundPathogenesis of MASLD and MASH – role of insulin resistance and lipotoxicity
Bansal, S. K., & Bansal, M. B. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17930 · Cited by 178
“What was previously known as non-alcoholic fatty liver disease (NAFLD) was changed to metabolic dysfunction-associated steatotic liver disease (MASLD) and MASH, previously known as non-alcoholic steatohepatitis (NASH), was changed to metabolic dysfunction-associated steatohepatitis.”
BackgroundAlcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives
Liu, S.-Y., Tsai, I.-T., & Hsu, Y.-C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105170 · Cited by 183
“Meanwhile, a splice variant in hydroxysteroid 17-β dehydrogenase 13 (HSD17B13) was identified as a candidate for protection against ALD in a recent study [44].”
BackgroundHa, S., Wong, V. W.-S., Zhang, X., & Yu, J. (2025) · Gut · doi:10.1136/gutjnl-2024-332398 · Cited by 181
“…to be protective against MASLD and mitigate liver injury in patients who are genetically predisposed to liver disease caused by PNPLA3 148M polymorphisms via reducing PNPLA3 mRNA expression, 43 suggesting the therapeutic potential of HSD17B13 rs72613567 in specific group of patients with MASLD.”
BackgroundManagement of non-alcoholic fatty liver disease
Petroni, M. L., Brodosi, L., Bugianesi, E., & Marchesini, G. (2021) · BMJ · doi:10.1136/bmj.m4747 · Cited by 177
The landscape of gene mutations in cirrhosis and hepatocellular carcinoma
Müller, M., Bird, T. G., & Nault, J.-C. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.01.019 · Cited by 178
“The development of mouse models where chronic liver disease and subsequent HCC development is driven by exogenous factors relevant to human disease, like ALD or NAFLD, will be crucial.”
BackgroundInfluentialPathophysiological mechanisms underlying MAFLD
Kuchay, M. S., Choudhary, N. S., & Mishra, S. K. (2020) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2020.09.026 · Cited by 177
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Do, A., Zahrawi, F., & Mehal, W. Z. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01084-2 · Cited by 169
“This genetic association was observed in several diseases, including alcoholic and non-alcoholic steatohepatitis 182 .”
The eMERGE Network, Namjou, B., Lingren, T., Huang, Y., Parameswaran, S., Cobb, B. L., Stanaway, I. B., Connolly, J. J., Mentch, F. D., Benoit, B., et al. (2019) · BMC Medicine · doi:10.1186/s12916-019-1364-z · Cited by 179
“This family of proteins plays an important role in lipid metabolism [48].”
BackgroundInfluentialSelf-citationLuukkonen, P. K., Qadri, S., Ahlholm, N., Porthan, K., Männistö, V., Sammalkorpi, H., Penttilä, A. K., Hakkarainen, A., Lehtimäki, T. E., Gaggini, M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.013 · Cited by 170
Carlsson, B., Lindén, D., Brolén, G., Liljeblad, M., Bjursell, M., Romeo, S., & Loomba, R. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15738 · Cited by 169
Alcohol-associated liver disease—Global epidemiology
Åberg, F., Jiang, Z. G., Cortez-Pinto, H., & Männistö, V. (2024) · Hepatology · doi:10.1097/hep.0000000000000899 · Cited by 163
“[55,56] Additionally, variations in genes such as ADH , ALDH , and dopamine receptors affect alcohol metabolism and dependence, shaping individual alcohol consumption behaviors and tolerance.”
Perakakis, N., Stefanakis, K., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154320 · Cited by 162
“Moreover, HSD17B13 has already been implied as a therapeutic target [42], while it was recently established that carriage of HSD17B13 rs6834314 diminishes the fibrotic effects of PNPLA3 rs738409, thus indicating a novel objective for pathway-targeting therapies [55].”
Mitochondria, oxidative stress and nonalcoholic fatty liver disease: A complex relationship
Karkucińska‐Więckowska, A., Simões, I. C. M., Kalinowski, P., Lebiedzińska, M., Zieniewicz, K., Milkiewicz, P., Górska‐Ponikowska, M., Pinton, P., Malik, A. N., Krawczyk, M. J., et al. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13622 · Cited by 197
Emdin, C. A., Haas, M. E., Khera, A. V., Aragam, K., Chaffin, M., Klarin, D., Hindy, G., Jiang, L., Wei, W.-Q., Feng, Q., et al. (2020) · PLOS Genetics · doi:10.1371/journal.pgen.1008629 · Cited by 161
“A. Association of known alcoholic and non-alcoholic cirrhosis variants with all-cause cirrhosis in UK Biobank To examine whether known alcoholic and non-alcoholic cirrhosis variants associate with all-cause cirrhosis, we tested the association of six known cirrhosis variants (PNPLA3 I48M, TM6SF2 E167K, MBOAT7 rs641738…”
BackgroundInfluentialSelf-citationFound in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Wang, S., & Friedman, S. L. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0759 · Cited by 158
“On the other hand, actionable SNPs such as the protective truncation variant in HSD17B13 ( 298 ) may be valuable by designing small interfering RNA (siRNA) therapies that replicate this SNP ’ s protective action in patients with a disease-promoting variant.”
BackgroundNoninvasive assessment of liver fibrosis in NAFLD
Sanyal, A. J., Castera, L., & Wong, V. W.-S. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.03.042 · Cited by 157
Genetic and epigenetic factors determining NAFLD risk
Jonas, W., & Schürmann, A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101111 · Cited by 176
“This effect was associated with a decrease in PNPLA3 mRNA in an allele dose-dependent manner [61].”
BackgroundOxidative Stress in NAFLD: Role of Nutrients and Food Contaminants
Rives, C., Fougerat, A., Ellero‐Simatos, S., Loiseau, N., Guillou, H., Gamet‐Payrastre, L., & Wahli, W. (2020) · Biomolecules · doi:10.3390/biom10121702 · Cited by 195
“Finally, polymorphisms within 17β-hydroxysteroid dehydrogenase type 13 (HSD17B13), a protein expressed at the surface of lipid droplets with retinol dehydrogenase activity, are associated with NAFLD, NASH, fibrosis, and cirrhosis [29,30].”
BackgroundSangro, P., de la Torre‐Aláez, M., Sangro, B., & D’Avola, D. (2023) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-023-00954-4 · Cited by 177
“Genetic variants in “glucokinase regulatory protein” ( GCKR ) gene [16], “solute carrier family 2-member 1” ( SLC2A1 ) gene [17], and “17-beta hydroxys-teroid dehydrogenase 13” ( HSD17B13 ) gene [18], have also been identified in patients with fatty liver disease.”
Backgroundrs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis
Teo, K., Abeysekera, K. W. M., Adams, L. A., Aigner, E. S., Anstee, Q. M., Bañales, J. M., Banerjee, R., Basu, P., Berg, T., Bhatnagar, P., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.027 · Cited by 168
“However, unlike variants in patatin-like phospholipase domain containing protein 3 (PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2), and 17b-hydroxysteroid dehydrogenase type 13 (HSD17B13), it was not identified to have genome-wide significance for liver fat or serum alanine aminotransferase (ALT).(1,10,11) Rs6…”
BackgroundSelf-citationJamialahmadi, O., Mancina, R. M., Ciociola, E., Tavaglione, F., Luukkonen, P. K., Baselli, G., Malvestiti, F., Thuillier, D., Raverdy, V., Männistö, V., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.023 · Cited by 148
History of Nonalcoholic Fatty Liver Disease
Lonardo, A., Leoni, S., Alswat, K., & Fouad, Y. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165888 · Cited by 169
Metabolic Targets in Nonalcoholic Fatty Liver Disease
Esler, W. P., & Bence, K. K. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.04.007 · Cited by 158
Portincasa, P., Khalil, M., Mahdi, L., Perniola, V., Idone, V., Graziani, A., Baffy, G., & Ciaula, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115640 · Cited by 181
“Additional findings involve genetic variants in the genes of “glucokinase regulatory protein” ( GCKR ) [52], “solute carrier family 2-member 1” ( SLC2A1 ) [53], and “17-beta hydroxysteroid dehydrogenase 13” ( HSD17B13 ) [54].”
BackgroundPirola, C. J., Garaycoechea, M. E., Flichman, D., Arrese, M. A., Martino, J. S., Gazzi, C., Castaño, G. O., & Sookoian, S. C. (2018) · Journal of Lipid Research · doi:10.1194/jlr.p089953 · Cited by 144
“truncation of the HSD17B13 protein (9).”
BackgroundMethodResultInfluentialIL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease
Park, J., Zhao, Y., Zhang, F., Zhang, S., Kwong, A. C., Zhang, Y., Hoffmann, H.-H., Bushweller, L., Wu, X., Ashbrook, A. W., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.022 · Cited by 138
Pathogenesis of NASH: the Impact of Multiple Pathways
Noureddin, M., & Sanyal, A. J. (2018) · Current Hepatology Reports · doi:10.1007/s11901-018-0425-7 · Cited by 149
Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
Ciaula, A. D., Passarella, S., Shanmugam, H., Noviello, M., Bonfrate, L., Wang, D. Q. ‐., & Portincasa, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105375 · Cited by 153
“The rs72613567:TA variant confers a reduced risk of nonalcoholic steatohepatitis (not steatosis) in human liver samples [16].”
BackgroundGenetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology
Sookoian, S. C., Pirola, C. J., Valenti, L. V. C., & Davidson, N. O. (2020) · Hepatology · doi:10.1002/hep.31229 · Cited by 132
“(47-51) HSD17B13 variants which protect against NAFLD progression are associated with reduced activity of the enzyme, with the original reports linking the association to reduced NASH but not to decreased hepatic steatosis,(51) suggesting that a loss-of-function HSD17B13 allele impairs NAFLD progression rather than in…”
BackgroundEmdin, C. A., Haas, M., Ajmera, V. H., Simon, T. G., Homburger, J. R., Neben, C. L., Jiang, L., Wei, W., Feng, Q., Zhou, A. Y., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.12.011 · Cited by 138
Chen, V. L., Du, X., Chen, Y., Kuppa, A., Handelman, S. K., Vohnoutka, R. B., Peyser, P. A., Palmer, N. D., Bielak, L. F., Halligan, B. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20870-1 · Cited by 139
Germline Mutations in CIDEB and Protection against Liver Disease
Verweij, N., Haas, M. E., Nielsen, J. B., Sosina, O. A., Kim, M., Akbari, P., De, T., Hindy, G., Bovijn, J., Persaud, T., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2117872 · Cited by 127
Self-citation
Metadata
- Authors
- Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., Stepanchick, A. N., Still, M. D., McCarthy, S., O’Dushlaine, C., Packer, J. S., Balasubramanian, S., Gosalia, N., Esopi, D., Kim, S. Y., Mukherjee, S., Lopez, A. E., Fuller, E. D., Penn, J., Chu, X., Luo, J. Z., Mirshahi, U. L., Carey, D. J., Still, C. D., Feldman, M. D., Small, A., Damrauer, S. M., Rader, D. J., Zambrowicz, B., Olson, W., Murphy, A. J., Borecki, I. B., Shuldiner, A. R., Reid, J. G., Overton, J. D., Yancopoulos, G. D., Hobbs, H. H., Cohen, J. C., Gottesman, O., Teslovich, T. M., Baras, A., Mirshahi, T., Gromada, J., & Dewey, F. E.
- Affiliations
- From the Regeneron Genetics Center (N.S.A.-H., A.H.L., C.S., S. McCarthy, C.O., J.S.P., S.B., N.G., S. Mukherjee, A.E.L., E.D.F., J.P., I.B.B., A.R.S., J.G.R., J.D.O., O.G., T.M.T., A.B., F.E.D.) and Regeneron Pharmaceuticals (X. Cheng, Y.X., P.S., Y.L., D.E., S.Y.K., B.Z., W.O., A.J.M., G.D.Y., J.G.), Tarrytown, NY; the University of Texas Southwestern Medical Center at Dallas, Dallas (J.K., S.S., H.H.H., J.C.C.); and Geisinger Health System, Danville (G.C.W., A.N.S., M.D.S., X. Chu, J.Z.L., U.L.M....
- Regeneron (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Geisinger Health System (US)
- University of Pennsylvania (US)
- ORCID
- Cheng, Xiping
- Li, Alexander H.
- Xin, Yurong
- Schurmann, Claudia
- Liu, Yashu
- Kozlitina, Julia
- Stender, Stefan
- Wood, G. Craig
- Still, Matthew D.
- O’Dushlaine, Colm
- Packer, Jonathan S.
- Balasubramanian, Suganthi
- Gosalia, Nehal
- Esopi, David
- Kim, Sun Y.
- Mukherjee, Semanti
- Lopez, Alexander E.
- Chu, Xin
- Luo, Jonathan Z.
- Mirshahi, Uyenlinh L.
- Carey, David J.
- Still, Christopher D.
- Feldman, Michael D.
- Small, Aeron
- Damrauer, Scott M.
- Rader, Daniel J.
- Zambrowicz, Brian
- Olson, William
- Murphy, Andrew J.
- Borecki, Ingrid B.
- Shuldiner, Alan R.
- Reid, Jeffrey G.
- Overton, John D.
- Hobbs, Helen H.
- Cohen, Jonathan C.
- Baras, Aris
- Mirshahi, Tooraj
- Gromada, Jesper
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03-22
- Volume
- 378
- Issue
- 12
- Pages
- 1096-1106
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6668033
- OpenAlex
- W2793543636
- Cited by
- 827
- References
- 32
- Citations by year
- 2026: 101 · 2025: 104 · 2024: 82 · 2023: 104 · 2022: 100 · 2021: 109 · 2020: 127 · 2019: 67 · 2018: 32
- FWCI
- 48.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Regeneron Pharmaceuticals
- Perelman School of Medicine, University of Pennsylvania
- Smilow Foundation
- National Institutes of Health (P30DK072488, UL1TR001105)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- HSD17B13, chronic liver disease, loss-of-function mutations, alcoholic liver disease, non-alcoholic liver disease, alcoholic cirrhosis, non-alcoholic cirrhosis, nonalcoholic steatohepatitis, steatosis, alanine aminotransferase, aspartate aminotransferase, PNPLA3, liver histopathology
- MeSH terms
- Exome Sequencing, Loss of Function Mutation, Alanine Transaminase, Aspartate Aminotransferases, Chronic Disease, Fatty Liver, Female, Genotype, Humans, Liver, Liver Diseases, Male, Genetic Variation, 17-Hydroxysteroid Dehydrogenases, Biomarkers, Linear Models, Sequence Analysis, RNA, Disease Progression, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.